Changes in adiposity and other cardiometabolic risk factors following Roux-en-Y gastric bypass: A 12-month prospective cohort study in Chinese patients

被引：4

作者：

Mazidi M. ^{[1
,2
]}

Gao H.-K. ^{[3
]}

Hui H. ^{[3
]}

Li L. ^{[3
]}

Ferns G.A. ^{[4
]}

机构：

[1] Key State Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Chaoyang, Beijing

[2] Institute of Genetics and Developmental Biology, International College, University of Chinese Academy of Science (IC-UCAS), West Beichen Road, Chaoyang

[3] Department of General Surgery, The General Hospital of Chinese People’s Armed Police Forces, Beijing

[4] Division of Medical Education, Brighton and Sussex Medical School, University of Brighton, Rm 342, Mayfield House, Brighton

来源：

Indian Journal of Gastroenterology | 2017年 / 36卷 / 4期

关键词：

Adiposity; Bariatric surgery; Cardiometabolic;

D O I：

10.1007/s12664-017-0774-0

中图分类号：

学科分类号：

摘要：

Aim: We aimed to investigate the changes in adiposity and other cardiometabolic risk factors in the year following Roux-en-Y gastric bypass (RYGB) in patients of Chinese ethnicity. Methods: The study recruited 209 patients who met the indications for bariatric surgery. Adiposity and cardiometabolic risk factors were assessed at baseline and over the 12 months following surgery in all participants. SPSS® software was used for statistical analysis. Results: The mean body mass index (BMI) was 29.98 kg/m2 at baseline and steadily decreased to 25.32 kg/m2 at 12 months, giving a relative change of −15.5% (p < 0.001). All of the lipid profile fractions except high-density lipoprotein (HDL) declined during the first 12 months of follow up; serum HDL increased during this time (all ANOVA p < 0.001). The mean fasting plasma glucose was 9.49 mmol/L at baseline and gradually decreased to 5.69 mmol/L at 12 months, giving a relative change of −40.0% (p < 0.001). Conclusion: Following the RYGB procedure, changes in measures of adiposity were paralleled by a significant improvement in cardiometabolic factors for 12 months after surgery. © 2017, Indian Society of Gastroenterology.

引用

页码：258 / 262

页数：4

共 34 条

[1]

Ahima R.S., Physiology L.M.A., The health risk of obesity—better metrics imperative, Science, 341, pp. 856-858, (2013)

[2]

Wang Y.C., McPherson K., Marsh T., Gortmaker S.L., Brown M., Health and economic burden of the projected obesity trends in the USA and the UK, Lancet, 378, pp. 815-825, (2011)

[3]

Kimokoti R.W., Millen B.E., Diet, the global obesity epidemic, and prevention, J Am Diet Assoc, 111, pp. 1137-1140, (2011)

[4]

King D., The future challenge of obesity, Lancet, 378, pp. 743-744, (2011)

[5]

Kouris-Blazos A., Wahlqvist M.L., Health economics of weight management: evidence and cost, Asia Pac J Clin Nutr, 16, pp. 329-338, (2007)

[6]

Hafeez S., Ahmed M.H., Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?, J Obes, 2013, (2013)

[7]

Fallahi-Shahabad S., Mazidi M., Tavasoli A., Et al., Metabolic improvement of morbid obese patients following Roux-en-Y gastric bypass surgery: a prospective study in Mashhad, Iran Indian J Gastroenterol, 35, pp. 195-200, (2016)

[8]

Mazidi M., de Caravatto P.P., Speakman J.R., Cohen R.V., Mechanisms of action of surgical interventions on weight-related diseases: the potential role of bile acids, Obes Surg, 27, pp. 826-836, (2017)

[9]

Sjostrom L., Lindroos A.K., Peltonen M., Et al., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery, N Engl J Med, 351, pp. 2683-2693, (2004)

[10]

Sjostrom L., Peltonen M., Jacobson P., Et al., Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications, JAMA, 311, pp. 2297-2304, (2014)

← 1 2 3 4 →